N2OFF, Inc. (NASDAQ: NITO) announced that its wholly‑owned subsidiary, MitoCareX Bio Ltd., has obtained preliminary in‑vitro data demonstrating that its proprietary MITOLINE™ platform can inhibit pro‑inflammatory responses in human immune cells, marking a significant milestone in the company’s biotechnology strategy.
The data, generated in early 2026, show that selected small‑molecule candidates reduce key inflammatory markers such as TNF‑α and IL‑6 in cultured human macrophages. The results support moving the most promising candidates into pre‑clinical studies and expanding the MITOLINE™ discovery engine to additional mitochondrial carrier targets, broadening the platform’s therapeutic scope.
N2OFF completed the acquisition of MitoCareX Bio in October 2025 for $700,000 in cash and a 40% equity stake. Sellers receive up to $1.6 million in financing proceeds over five years, and N2OFF committed $1 million in cash over two years. The transaction closed after stockholder approval in September 2025 and is now fully integrated into N2OFF’s biotech portfolio.
The anti‑inflammatory drug market is projected to grow from $122 billion in 2024 to $275 billion by 2034, while metabolic disorder therapeutics are expected to rise from $77 billion in 2024 to $120 billion by 2030. The data suggest that MitoCareX’s platform could capture a share of these expanding markets by targeting mitochondrial carriers, a class of proteins historically difficult to drug.
The positive in‑vitro results reinforce N2OFF’s pivot from a primarily cleantech and agri‑food company to a diversified enterprise with a growing biotechnology arm. The company’s dual focus positions it to leverage its existing capital and expertise while pursuing high‑growth therapeutic opportunities, potentially broadening revenue streams beyond its renewable‑energy assets.
Investors responded positively to the announcement, reflecting confidence in the platform’s potential and the company’s strategic shift, though the long‑term impact on valuation remains to be seen as further pre‑clinical data and regulatory milestones are required.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.